 LONDON and NEW YORK, Nov. 19, 2020 GLOBE NEWSWIRE -- MeiraGTx Holdings plc Nasdaq:MGTX, a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 of its ordinary shares at a public offering price of 12.85 per share. In addition, MeiraGTx has granted the underwriters a 30-day option to purchase up to an additional 750,000 of its ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds to MeiraGTx from the offering are expected to be approximately 64.3 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters option. All of the ordinary shares in the offering are being sold by MeiraGTx. 